<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X12451058</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X12451058</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse</article-title>
<subtitle>Negative-Pressure Wound Therapy for Severe Pressure Ulcers</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Soares</surname><given-names>Marta O.</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Dumville</surname><given-names>Jo C.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Ashby</surname><given-names>Rebecca L.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Iglesias</surname><given-names>Cynthia P.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Bojke</surname><given-names>Laura</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Adderley</surname><given-names>Una</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>McGinnis</surname><given-names>Elizabeth</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Stubbs</surname><given-names>Nikki</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Torgerson</surname><given-names>David J.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Claxton</surname><given-names>Karl</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Cullum</surname><given-names>Nicky</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X12451058">Centre for Health Economics, The University of York, York, UK (MOS, LB, KC)</aff>
<aff id="aff2-0272989X12451058">Department of Health Sciences, The University of York, York, UK (JCD, RLA, CI, DT)</aff>
<aff id="aff3-0272989X12451058">School of Health and Social Care, Teesside University, Middlesbrough, UK (UA)</aff>
<aff id="aff4-0272989X12451058">Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds General Infirmary, Leeds, UK (EM)</aff>
<aff id="aff5-0272989X12451058">NHS Leeds Community Healthcare, St Mary’s Hospital, Leeds, UK (NS)</aff>
<aff id="aff6-0272989X12451058">School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK (NC)</aff>
<author-notes>
<corresp id="corresp1-0272989X12451058">Marta O. Soares, The University of York, Centre for Health Economics, Alcuin A Block, Heslington, York, YO10 5DD, UK; e-mail: <email>marta.soares@york.ac.uk</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>3</issue>
<issue-title>Special Issue: Health Technology Assessment to Inform Policy</issue-title>
<fpage>415</fpage>
<lpage>436</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>2</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>3</month>
<year>2012</year>
</date>
</history>
<abstract>
<p>Health care resources are scarce, and decisions have to be made about how to allocate funds. Often, these decisions are based on sparse or imperfect evidence. One such example is negative-pressure wound therapy (NPWT), which is a widely used treatment for severe pressure ulcers; however, there is currently no robust evidence that it is effective or cost-effective. This work considers the decision to adopt NPWT given a range of alternative treatments, using a decision analytic modeling approach. Literature searches were conducted to identify existing evidence on model parameters. Given the limited evidence base, a second source of evidence, beliefs elicited from experts, was used. Judgments from experts on relevant (uncertain) quantities were obtained through a formal elicitation exercise. Additionally, data derived from a pilot trial were also used to inform the model. The 3 sources of evidence were collated, and the impact of each on cost-effectiveness was evaluated. An analysis of the value of further information indicated that a randomized controlled trial may be worthwhile in reducing decision uncertainty, where from a set of alternative designs, a 3-arm trial with longer follow-up was estimated to be the most efficient. The analyses presented demonstrate how allocation decisions about medical technologies can be explicitly informed when data are sparse and how this kind of analyses can be used to guide future research prioritization, not only indicating whether further research is worthwhile but what type of research is needed and how it should be designed.</p>
</abstract>
<kwd-group>
<kwd>Markov model</kwd>
<kwd>elicited evidence</kwd>
<kwd>pilot trial</kwd>
<kwd>negative pressure wound therapy</kwd>
<kwd>sparse</kwd>
<kwd>evidence synthesis</kwd>
<kwd>expected value of information</kwd>
<kwd>research design</kwd>
<kwd>cost-effectiveness analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Health professionals and decision-making bodies should use existing research evidence (regarding clinical and cost-effectiveness) to inform their decisions regarding the adoption of health care interventions.<sup><xref ref-type="bibr" rid="bibr1-0272989X12451058">1</xref></sup> However, there are many situations where only sparse data are available to inform these decisions. This common problem places decision makers in a difficult position. Limited data may delay a formal evaluation, leaving people uninformed, with ad hoc use of a technology that may offer less value than alternatives.</p>
<p>In this article, we demonstrate how analyses to inform adoption and research decisions can be conducted when the evidence base is sparse. This process requires characterization of all sources of uncertainty and the assessment of decision uncertainty and its consequences; therefore, all available evidence must be utilized. In the absence of robust research data but the presence of substantial practical experience of using the treatment of interest and its comparators, evidence may include expert opinion. Expert knowledge can be captured quantitatively and hence used to inform a cost-effectiveness model by applying formal methods to elicit experts’ beliefs.<sup><xref ref-type="bibr" rid="bibr2-0272989X12451058">2</xref></sup></p>
<sec id="section1-0272989X12451058">
<title>Motivating Example</title>
<p>Negative-pressure wound therapy (NPWT) is a medical device used to treat full-thickness wounds, such as severe (grades 3 and 4) pressure ulcers. It has been claimed that NPWT speeds healing and reduces infection rates and costs as well as facilitating wound management.<sup><xref ref-type="bibr" rid="bibr3-0272989X12451058">3</xref>,<xref ref-type="bibr" rid="bibr4-0272989X12451058">4</xref></sup> However, there is very little research evidence for the clinical or cost-effectiveness of NPWT,<sup><xref ref-type="bibr" rid="bibr3-0272989X12451058">3</xref>,<xref ref-type="bibr" rid="bibr5-0272989X12451058">5</xref></sup> even though it is a relatively expensive treatment, used widely in the developed world. Therefore, there is a need to evaluate the cost-effectiveness of NPWT and alternative treatments for its various indications, including severe pressure ulcers.</p>
<p>In this case study, the population of interest was UK patients with severe pressure ulcers. The alternatives to NPWT for this patient population are dressings and topical treatments, with several different treatment options and limited evidence to guide treatment choice. Thus, we conducted an electronic survey of nurses involved in wound care (in the UK, most wound care is nurse led). Respondents (<italic>n</italic> = 28) were asked to identify possible alternatives to NPWT and to rank these in order of preference. Subsequently, we established a panel of senior expert nurses (<italic>n</italic> = 7) and used the nominal group technique<sup><xref ref-type="bibr" rid="bibr6-0272989X12451058">6</xref></sup> to establish the level of consensus regarding the alternative treatment options identified in the survey. This panel, in common with the survey results, identified spun hydrocolloid (hydrofiber), alginate, and foam dressings as relevant comparators. Alongside the cost-effectiveness study, we also conducted a pilot randomized controlled trial (RCT) to assess the feasibility of conducting a further study on NPWT. Dressing use in the standard care arm of this pilot trial was limited to spun hydrocolloid (hydrofiber), alginate, and foam.</p>
</sec>
<sec id="section2-0272989X12451058">
<title>Analytic Framework</title>
<sec id="section3-0272989X12451058">
<title>Cost-Effectiveness and Decision Uncertainty</title>
<p>Decisions based on expected cost-effectiveness should not only consider the expected health gain associated with a specific technology but also the potential health gains forgone elsewhere due to additional costs associated with the technology displacing other National Health Service (NHS) activities. This can be expressed using the net health benefit (NHB) statistic for a defined willingness to pay value.<sup><xref ref-type="bibr" rid="bibr7-0272989X12451058">7</xref>,<xref ref-type="bibr" rid="bibr8-0272989X12451058">8</xref></sup> The NHB of a treatment <italic>t</italic> informed by the set of input parameters, <inline-formula id="inline-formula1-0272989X12451058"><mml:math display="inline" id="math1-0272989X12451058"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula>, can be defined as <inline-formula id="inline-formula2-0272989X12451058"><mml:math display="inline" id="math2-0272989X12451058"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mtext>effects</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mtext>costs</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:math></inline-formula>, where <inline-formula id="inline-formula3-0272989X12451058"><mml:math display="inline" id="math3-0272989X12451058"><mml:mrow><mml:mi>λ</mml:mi></mml:mrow></mml:math></inline-formula> is the cost-effectiveness threshold. Unless otherwise stated, a cost-effectiveness threshold of £20,000 per quality-adjusted life year (QALY) was assumed.<sup><xref ref-type="bibr" rid="bibr7-0272989X12451058">7</xref></sup></p>
<p>The process of explicitly structuring and combining all available evidence in these evaluations often relies on the use of decision analytic models (DAMs). A DAM aims to represent disease progression and often model transitions between key health states; the costs and consequences associated with these states (in relation to the relevant health technologies) can then be assessed. If we knew the true values of costs and effects, the optimal decision <italic>D</italic> would be made by choosing the treatment with the highest NHB. Yet, evidence used to inform the DAM is often uncertain; an adopt or reject decision rooted in available evidence should be based on expected values: in this case, the optimal treatment is that which offers the highest expected NHB; that is, <inline-formula id="inline-formula4-0272989X12451058"><mml:math display="inline" id="math4-0272989X12451058"><mml:mrow><mml:mtext>D</mml:mtext><mml:mo>:</mml:mo><mml:mspace width="0.25em"/><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>:</mml:mo><mml:mi>t</mml:mi><mml:mo>∈</mml:mo><mml:mi>T</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <italic>t</italic> represents the optimal treatment out of a set of treatments <italic>T</italic>.</p>
<p>To evaluate the cost-effectiveness of NPWT for the treatment of severe pressure ulcers, a DAM was designed and literature searches conducted to identify evidence to inform model parameters. Evidence from the literature was found to be few and sparse, failing to adequately characterize the events that clinical experts identified as relevant for inclusion in the DAM (see the next section). Limited evidence meant that we would either be unable to proceed with the evaluation or that further analytic assumptions would be required. We were aware, however, that the treatments of interest were being used in clinical practice, and thus, there was some expertise regarding the characteristics and outcomes of relevant patients. To collect this evidence, we used formal methods for the elicitation of expert opinion. A full report of this process is reported separately<sup><xref ref-type="bibr" rid="bibr8-0272989X12451058">8</xref></sup>; however, a brief summary is provided in a later section. The evidence generated by the pilot trial was also used as an additional evidence source for the DAM.</p>
<p>Because 3 sources of evidence (literature, elicitation, and pilot trial data) were potentially available to inform a single model parameter, alternative sources were combined so that the impact of each source of evidence on cost-effectiveness could be evaluated.</p>
<p>The perspective of the analysis was that of the UK NHS, with costs presented in pounds sterling (£) at 2008-2009 prices. Costs and health benefits were discounted at 3.5%.<sup><xref ref-type="bibr" rid="bibr7-0272989X12451058">7</xref></sup> We implemented an incremental analysis. The DAM was probabilistic, where uncertainty was propagated using a Monte Carlo simulation.<sup><xref ref-type="bibr" rid="bibr9-0272989X12451058">9</xref></sup> Decision uncertainty was presented as the probability that each treatment has the highest expected NHB (i.e., is expected to be cost-effective).</p>
</sec>
<sec id="section4-0272989X12451058">
<title>Value of Further Research</title>
<p>Given the uncertainty around treatment decisions, it is important to explore whether investing in further research to reduce such decision uncertainty is worthwhile and, if so, what type of future research is most likely to offer the most value for the money.</p>
<p>To explore these issues, value of further research analyses were implemented.<sup><xref ref-type="bibr" rid="bibr10-0272989X12451058">10</xref><xref ref-type="bibr" rid="bibr11-0272989X12451058"/><xref ref-type="bibr" rid="bibr12-0272989X12451058"/>–<xref ref-type="bibr" rid="bibr13-0272989X12451058">13</xref></sup> The maximum potential value of additional evidence to inform this decision problem can be represented by the expected value of perfect information (EVPI). The EVPI is defined as the difference between the NHB, which might be achieved when the uncertainties are resolved (and different treatment choices made), and the expected NHB based on current evidence; that is, <inline-formula id="inline-formula5-0272989X12451058"><mml:math display="inline" id="math5-0272989X12451058"><mml:mrow><mml:mtext>EVPI</mml:mtext><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>.</p>
<p>The value of resolving the uncertainty associated with one, or a subset of parameters, (parameter EVPI) can also be estimated by <inline-formula id="inline-formula6-0272989X12451058"><mml:math display="inline" id="math6-0272989X12451058"><mml:mrow><mml:mtext>EVPI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>υ</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>υ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>υ</mml:mi></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msup><mml:mrow><mml:mo>|</mml:mo><mml:mi>υ</mml:mi></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <inline-formula id="inline-formula7-0272989X12451058"><mml:math display="inline" id="math7-0272989X12451058"><mml:mrow><mml:mi>υ</mml:mi></mml:mrow></mml:math></inline-formula> is the subset of parameters, from <inline-formula id="inline-formula8-0272989X12451058"><mml:math display="inline" id="math8-0272989X12451058"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula> being evaluated and <inline-formula id="inline-formula9-0272989X12451058"><mml:math display="inline" id="math9-0272989X12451058"><mml:mrow><mml:msup><mml:mrow><mml:mi>υ</mml:mi></mml:mrow><mml:mrow><mml:mtext>c</mml:mtext></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> the remaining parameters on <inline-formula id="inline-formula10-0272989X12451058"><mml:math display="inline" id="math10-0272989X12451058"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula>. Investigating the parameter EVPI can highlight the type of evidence that would be most valuable, indicating the research designs that might be required.</p>
<p>Estimates of the EVPI place an upper bound on the value of research, assuming that all uncertainty could be resolved. However, research will generate data from a sample of the population of interest that can only be expected to reduce, rather than eliminate, uncertainty. By predicting the range of possible sample results for a particular research design and sample size, and calculating the NHB of subsequent treatment choices for each possible sample result, the expected value of sample information (EVSI) can also be established.<sup><xref ref-type="bibr" rid="bibr12-0272989X12451058">12</xref></sup> The EVSI represents the expected benefits of particular research designs.<sup><xref ref-type="bibr" rid="bibr10-0272989X12451058">10</xref></sup> The EVSI can be estimated by <inline-formula id="inline-formula11-0272989X12451058"><mml:math display="inline" id="math11-0272989X12451058"><mml:mrow><mml:mtext>EVSI</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>υ</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mtext>E</mml:mtext><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mi>t</mml:mi></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munder><mml:mtext>E</mml:mtext><mml:mrow><mml:msup><mml:mi>υ</mml:mi><mml:mtext>c</mml:mtext></mml:msup><mml:mo>,</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>υ</mml:mi><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mi>d</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mi>t</mml:mi><mml:mi mathvariant="bold">θ</mml:mi></mml:msubsup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:munder><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mi>t</mml:mi></mml:munder><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munder><mml:mtext>E</mml:mtext><mml:mi mathvariant="bold">θ</mml:mi></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mi>t</mml:mi><mml:mi mathvariant="bold">θ</mml:mi></mml:msubsup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. The first term in this equation represents the NHB associated with the range of possible, unknown results of research (data). How data were generated is detailed ahead in this article.</p>
<p>To choose between alternative designs, the costs as well as the benefits of research need to be considered. The difference between the EVSI and the estimated costs of that chosen particular research design/study is the expected net benefit of sampling (ENBS). Further research is expected to be worthwhile if the ENBS is positive, indicating that more efficient research designs (including choice of sample size) will generate a higher ENBS.</p>
<p>Calculations of the value of further research can be computationally burdensome, especially when nested expectations need to be evaluated. Specificities of the implementation of these analyses (simplifying assumptions and estimation strategy used) are detailed in the relevant sections below.</p>
</sec>
</sec>
<sec id="section5-0272989X12451058">
<title>Structuring the Decision Problem</title>
<p>A DAM was developed with clinical input to ensure that it adequately represented the clinical trajectory of patients with severe pressure ulceration, including all events relevant to cost-effectiveness. The model was based on 3 transition states: unhealed, healed, and dead (<xref ref-type="fig" rid="fig1-0272989X12451058">Figure 1</xref>).</p>
<fig id="fig1-0272989X12451058" position="float">
<label>Figure 1</label>
<caption>
<p>Decision analytic model for the treatment of severe (grades 3 and 4) pressure ulcers. In secondary healing, the wound closes spontaneously by contraction and re-epithelialization.</p>
</caption>
<graphic xlink:href="10.1177_0272989X12451058-fig1.tif"/>
</fig>
<p>Surgery to close the wound (“closure surgery”), wound-related complications (osteomyelitis or systemic infection), and treatment changes were included as relevant events associated with the transition states. Patients remaining in state 1, unhealed, were assumed to incur costs related to the treatment of their ulcer and the possible presence of wound-related complications. Longer stays in this state would result in higher incurred costs. Transition to state 2, healed, could be a consequence of either healing by secondary intention or closure surgery, with the occurrence, outcomes, and costs of each form of closure being considered separately. Closure surgery was not considered as an alternative to NPWT in treating severe pressure ulcers because the clinicians advising on the development of the DAM noted that a decision to undertake surgery would occur downstream of treatment with NPWT and/or dressings. Transitions to death could occur for healed and unhealed patients. Details of all model transitions, relevant events, and associated costs and outcomes are in <xref ref-type="table" rid="table1-0272989X12451058">Tables 1</xref>, <xref ref-type="table" rid="table2-0272989X12451058">2</xref>, and <xref ref-type="table" rid="table3-0272989X12451058">3</xref>. A time horizon of 2 years and a cycle length of 4 weeks were used. Outcomes were measured as health care costs per QALY gained.</p>
<table-wrap id="table1-0272989X12451058" position="float">
<label>Table 1</label>
<caption>
<p>Parameters Regarding Transitions: Density Functions and Summary Descriptions of the Evidence Derived from Distinct Sources</p>
</caption>
<graphic alternate-form-of="table1-0272989X12451058" xlink:href="10.1177_0272989X12451058-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Existing Evidence (1)<hr/></th>
<th align="center">Elicited Evidence (2)<hr/></th>
<th align="center">Existing + Elicited Evidence (3)<hr/></th>
<th align="center">Pilot Trial<sup><xref ref-type="table-fn" rid="table-fn2-0272989X12451058">a</xref></sup> (4)<hr/></th>
<th align="center">Existing + Elicited + Pilot Trial Evidence (5)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Parameter</th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center"><italic>n</italic> of <italic>N</italic><sup><xref ref-type="table-fn" rid="table-fn3-0272989X12451058">b</xref></sup></th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center">(1), (3), and (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Log hazard of healing when treated with HC (up to 6 months)</td>
<td><graphic id="img1-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img1.tif"/></td>
<td><graphic id="img2-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img2.tif"/></td>
<td><graphic id="img3-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img3.tif"/></td>
<td>0 of 4</td>
<td><graphic id="img4-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img4.tif"/></td>
<td><graphic id="img5-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img5.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC, −3.95 (–4.50 to −3.46)</td>
<td>Normal, −3.74 (−5.96 to −1.52)</td>
<td>MCMC, −3.97 (−4.59 to −3.46)</td>
<td/>
<td>MCMC, −3.96 (−4.55 to −3.47)</td>
<td/>
</tr>
<tr>
<td>Log hazard of healing after 6 months, assumed independent of treatment<sup><xref ref-type="table-fn" rid="table-fn4-0272989X12451058">c</xref></sup></td>
<td>NA</td>
<td><graphic id="img6-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img6.tif"/></td>
<td>Same as (2)</td>
<td>NA</td>
<td>Same as (2)</td>
<td>Same as (2)</td>
</tr>
<tr>
<td/>
<td/>
<td>Normal, −4.28 (−10.24 to 1.67)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Log hazard ratio of healing for F relative to HC<sup><xref ref-type="table-fn" rid="table-fn5-0272989X12451058">d</xref></sup></td>
<td><graphic id="img7-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img7.tif"/></td>
<td><graphic id="img8-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img8.tif"/></td>
<td><graphic id="img9-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img9.tif"/></td>
<td>0 of 1</td>
<td><graphic id="img10-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img10.tif"/></td>
<td><graphic id="img11-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img11.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC, 0.03 (−1.97 to 1.86)</td>
<td>Normal, −0.96 (−6.32 to 4.40)</td>
<td>MCMC, −0.91 (−2.14 to 0.21)</td>
<td/>
<td>MCMC, −0.98 (−2.12 to 0.18)</td>
<td/>
</tr>
<tr>
<td>Log hazard ratio of healing for ALG relative to HC</td>
<td><graphic id="img12-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img12.tif"/></td>
<td><graphic id="img13-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img13.tif"/></td>
<td><graphic id="img14-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img14.tif"/></td>
<td>0 of 1</td>
<td><graphic id="img15-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img15.tif"/></td>
<td><graphic id="img16-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img16.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC, −0.19 (−1.76 to 1.13)</td>
<td>Normal, 0.003 (−0.63 to 0.64)</td>
<td>MCMC, −0.27 (−2.12 to 1.57)</td>
<td/>
<td>MCMC, −0.34 (−2.21 to 1.47)</td>
<td/>
</tr>
<tr>
<td>Log hazard ratio of healing for NPWT relative to HC</td>
<td><graphic id="img17-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img17.tif"/></td>
<td><graphic id="img18-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img18.tif"/></td>
<td><graphic id="img19-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img19.tif"/></td>
<td>1 of 6</td>
<td><graphic id="img20-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img20.tif"/></td>
<td><graphic id="img21-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img21.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC, 0.18 (−2.17 to 2.63)</td>
<td>Normal, 0.45 (−0.66 to 1.56)</td>
<td>MCMC, 0.47 (−1.18 to 2.10)</td>
<td/>
<td>MCMC, 0.75 (−0.88 to 2.34)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X12451058">
<p>Note: Columns (1), (2), and (4) relate to information derived from existing, elicited, and pilot trial evidence, respectively, while densities in (3) and (5) relate to the collation of these individual sources of evidence using Bayesian updating. NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; OM = osteomyelitis; SI = systemic infection; MCMC = Markov chain Monte Carlo; NA = not available.</p>
</fn>
<fn id="table-fn2-0272989X12451058">
<label>a.</label>
<p>Within the pilot trial, participants in the standard care arm could be treated with spun hydrocolloid, alginate, and foam; for the purpose of this analysis, these were assumed to be allocated at random.</p>
</fn>
<fn id="table-fn3-0272989X12451058">
<label>b.</label>
<p>Number of patients for whom the event of interest (healing) occurred, <italic>n</italic>, out of the total patients of interest (patients randomized to the treatment of interest), <italic>N</italic>.</p>
</fn>
<fn id="table-fn4-0272989X12451058">
<label>c.</label>
<p>This parameter was elicited using the following question: “Think only of those patients who still have a grade 3 or 4 pressure ulcer 6 months after starting treatment with HC. What proportion of them do you think would heal their reference ulcer between 6 and 12 months?”<sup><xref ref-type="bibr" rid="bibr2-0272989X12451058">2</xref></sup> The upper bound of 12 months was used to ease the task of experts. In the model, however, the log hazard derived was applied to the end of the time horizon.</p>
</fn>
<fn id="table-fn5-0272989X12451058">
<label>d.</label>
<p>The existing evidence of foam, F, consisted of a trial where zero events were reported in both arms. These data are not informative, and a relative treatment effect was not estimable. To allow obtaining an estimate of the treatment effect of foam under this scenario, a common (but random) effect of dressing treatments was assumed.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0272989X12451058" position="float">
<label>Table 2</label>
<caption>
<p>Parameters Regarding Relevant Events: Density Functions and Summary Descriptions of the Evidence Derived from Distinct Sources</p>
</caption>
<graphic alternate-form-of="table2-0272989X12451058" xlink:href="10.1177_0272989X12451058-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Existing Evidence (1)<hr/></th>
<th align="center">Elicited Evidence (2)<hr/></th>
<th align="center">Existing + Elicited Evidence (3)<hr/></th>
<th align="center">Pilot Trial (4)<hr/></th>
<th align="center">Existing + Elicited + Pilot Trial Evidence (5)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Parameter</th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th/>
<th align="center"><italic>n</italic> of <italic>N</italic><sup><xref ref-type="table-fn" rid="table-fn7-0272989X12451058">a</xref></sup></th>
<th align="center">Distribution, Mean, and Credible Interval</th>
<th align="center">(1), (3), and (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintained treatment, % of patients being treated with the same treatment 6 months after starting treatment</td>
<td>NA</td>
<td><graphic id="img22-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img22.tif"/></td>
<td>Same as (2)</td>
<td>1 of 12</td>
<td><graphic id="img23-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img23.tif"/></td>
<td><graphic id="img24-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img24.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Beta(0.85 to 1.58)</td>
<td/>
<td/>
<td>Beta(1.85 to 12.58)</td>
<td/>
</tr>
<tr>
<td>Probability of having had surgery conditional on having healed (proportion of healed patients who achieved healing through surgery, <inline-formula id="inline-formula12-0272989X12451058"><mml:math display="inline" id="math12-0272989X12451058"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>H</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>)</td>
<td>NA</td>
<td><graphic id="img25-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img25.tif"/></td>
<td>Same as (2)</td>
<td>0 of 1</td>
<td><graphic id="img26-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img26.tif"/></td>
<td><graphic id="img27-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img27.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Beta(0.39 to 2.16)</td>
<td/>
<td/>
<td>Beta(0.39 to 3.16)</td>
<td/>
</tr>
<tr>
<td>Probability of healing conditional on having undertaken closure surgery (proportion of patients healed after surgery, <inline-formula id="inline-formula13-0272989X12451058"><mml:math display="inline" id="math13-0272989X12451058"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>)</td>
<td>NA</td>
<td><graphic id="img28-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img28.tif"/></td>
<td>Same as (2)</td>
<td>NA</td>
<td>Same as (2)</td>
<td><graphic id="img29-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img29.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Beta(1.42 to 0.92)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Unhealed patients presenting with complications after starting treatment with HC</td>
<td>NA</td>
<td><graphic id="img30-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img30.tif"/></td>
<td>Same as (2)</td>
<td>0 of 4</td>
<td><graphic id="img31-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img31.tif"/></td>
<td><graphic id="img32-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img32.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Beta(1.57 to 2.06)</td>
<td/>
<td/>
<td>Beta(1.57 to 6.06)</td>
<td/>
</tr>
<tr>
<td>Hazard ratio of complication occurrence in unhealed patients treated with F in relation to HC<sup><xref ref-type="table-fn" rid="table-fn8-0272989X12451058">b</xref></sup></td>
<td>NA</td>
<td><graphic id="img33-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img33.tif"/></td>
<td>Same as (2)</td>
<td>0 of 1</td>
<td>Same as (2)</td>
<td><graphic id="img34-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img34.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Normal(0.16 to 0.62)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Hazard ratio of complication occurrence in unhealed patients treated with ALG relative to HC<sup><xref ref-type="table-fn" rid="table-fn8-0272989X12451058">b</xref></sup></td>
<td>NA</td>
<td><graphic id="img35-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img35.tif"/></td>
<td>Same as (2)</td>
<td>0 of 1</td>
<td>Same as (2)</td>
<td><graphic id="img36-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img36.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Normal(0.04 to 0.43)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Log hazard ratio of complication occurrence in unhealed patients treated with NPWT relative to HC<sup><xref ref-type="table-fn" rid="table-fn8-0272989X12451058">b</xref></sup></td>
<td>NA</td>
<td><graphic id="img37-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img37.tif"/></td>
<td>Same as (2)</td>
<td>0 of 6</td>
<td>Same as (2)</td>
<td><graphic id="img38-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img38.tif"/></td>
</tr>
<tr>
<td/>
<td/>
<td>Normal(−0.16 to 0.74)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0272989X12451058">
<p>Note: Columns (1), (2), and (4) relate to information derived from existing, elicited, and pilot trial evidence, respectively, while densities in (3) and (5) relate to the collation of these individual sources of evidence using Bayesian updating. NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; OM = osteomyelitis; SI = systemic infection; MCMC = Markov chain Monte Carlo; NA = not available.</p>
</fn>
<fn id="table-fn7-0272989X12451058">
<label>a.</label>
<p>Number of patients for whom the event (e.g., complications) occurred, <italic>n</italic>, out of the total patients of interest, <italic>N</italic>.</p>
</fn>
<fn id="table-fn8-0272989X12451058">
<label>b.</label>
<p>Pilot trial data were not included due to tractability issues.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0272989X12451058" position="float">
<label>Table 3</label>
<caption>
<p>Evidence from Distinct Sources Used to Describe Stochastic (Uncertain) Parameters of the Decision Model Regarding Costs and Utilities</p>
</caption>
<graphic alternate-form-of="table3-0272989X12451058" xlink:href="10.1177_0272989X12451058-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Existing Evidence (1)<hr/></th>
<th align="center">Elicited Evidence (2)<hr/></th>
<th align="center">Existing + Elicited Evidence (3)<hr/></th>
<th align="center">Pilot Trial (4)<hr/></th>
<th align="center">Existing + Elicited + Pilot Trial Evidence (5)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Parameter</th>
<th align="center">Distribution and Specified Parameter Values, or, for MCMC, Mean and Credible Interval</th>
<th align="center">Distribution and Specified Parameter Values, or, for MCMC, Mean and Credible Interval</th>
<th align="center">Distribution and Specified Parameter Values, or, for MCMC, Mean and Credible Interval</th>
<th align="center">Mean, SE, and Distribution</th>
<th align="center">Distribution and Specified Parameter Values, or, for MCMC, Mean and Credible Interval</th>
<th align="center">(1), (3), and (5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costs per week (£) incurred by unhealed patients, no complications</td>
<td><graphic id="img39-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img39.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>NA</td>
<td>Same as (1)</td>
<td><graphic id="img40-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img40.tif"/></td>
</tr>
<tr>
<td/>
<td>Gamma(0.275–1000)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Additional weekly costs (£) incurred by unhealed patients with complications, in relation to patients without</td>
<td><graphic id="img41-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img41.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>NA</td>
<td>Same as (1)</td>
<td><graphic id="img42-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img42.tif"/></td>
</tr>
<tr>
<td/>
<td>Gamma(1.212–1000)</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Number of dressing changes per week for patients on NPWT<sup><xref ref-type="table-fn" rid="table-fn10-0272989X12451058">a</xref></sup></td>
<td><graphic id="img43-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img43.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>Mean = 4.08; SE = 0.84; normal</td>
<td><graphic id="img44-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img44.tif"/></td>
<td><graphic id="img45-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img45.tif"/></td>
</tr>
<tr>
<td/>
<td>Normal(3–100), I(2,4)</td>
<td/>
<td/>
<td/>
<td>MCMC, 3.44 2.37–3.98)</td>
<td/>
</tr>
<tr>
<td>Number of changes of dressings (HC, ALG, F) per week<sup><xref ref-type="table-fn" rid="table-fn10-0272989X12451058">a</xref></sup></td>
<td><graphic id="img46-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img46.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>Mean = 6.15; SE = 0.47; normal</td>
<td><graphic id="img47-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img47.tif"/></td>
<td><graphic id="img48-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img48.tif"/></td>
</tr>
<tr>
<td/>
<td>Normal(4–100), I(2,7)</td>
<td/>
<td/>
<td/>
<td>MCMC, 5.74 (4.70–6.67)</td>
<td/>
</tr>
<tr>
<td>Utility associated with being pressure ulcer free, healed</td>
<td><graphic id="img49-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img49.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>NA</td>
<td><graphic id="img50-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img50.tif"/></td>
<td><graphic id="img51-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img51.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC: 0.686 (0.682–0.690)</td>
<td/>
<td/>
<td/>
<td>MCMC, 0.687 (0.684–0.692)</td>
<td/>
</tr>
<tr>
<td>Utility associated with having a pressure ulcer, unhealed</td>
<td><graphic id="img52-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img52.tif"/></td>
<td>NA</td>
<td>Same as (1)</td>
<td>Mean = 0.110; SE = 0.097; normal</td>
<td><graphic id="img53-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img53.tif"/></td>
<td><graphic id="img54-0272989X12451058" position="anchor" xlink:href="10.1177_0272989X12451058-img54.tif"/></td>
</tr>
<tr>
<td/>
<td>MCMC: 0.660 (0.645–0.675)</td>
<td/>
<td/>
<td/>
<td>MCMC, 0.657 (0.634–0.680)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0272989X12451058">
<p>Note: Columns (1), (2), and (4) relate to information derived from existing, elicited, and pilot trial evidence, respectively, while densities in (3) and (5) relate to the collation of these individual sources of evidence using Bayesian updating. SE = standard error; NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; OM = osteomyelitis; SI = systemic infection; MCMC = Markov chain Monte Carlo; NA = not available.</p>
</fn>
<fn id="table-fn10-0272989X12451058">
<label>a.</label>
<p>While dressing changes for comparator treatments were assumed to take place every 1 to 3 days (standard practice, informed by clinical opinion), for NPWT, dressings were assumed to be changed every 2 to 3 days following manufacturers’ recommendations.<sup><xref ref-type="bibr" rid="bibr50-0272989X12451058">50</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section6-0272989X12451058">
<title>Sources of Evidence</title>
<p>To inform the DAM, 3 sources of evidence were considered: existing data (from literature searches), elicited beliefs, and data derived from a pilot trial. This section describes the available sources of evidence and the methods used to collect and/or synthesize the evidence.</p>
<sec id="section7-0272989X12451058">
<title>Existing Evidence</title>
<p>Existing evidence was identified using literature reviews. The reviews focused on specific questions, reflecting the data required.<sup><xref ref-type="bibr" rid="bibr14-0272989X12451058">14</xref></sup> Existing data were sparse and only identified for the following parameters.</p>
<sec id="section8-0272989X12451058">
<title>Relative effectiveness</title>
<p>Systematic searches were conducted to identify all studies that contained data on the relative effectiveness of NPWT and dressings to treat severe (grade 3 and/or grade 4) pressure ulcers. The outcome of interest was an objective measure of wound healing. One RCT evaluating NPWT<sup><xref ref-type="bibr" rid="bibr15-0272989X12451058">15</xref></sup> and 11 evaluating dressings<sup><xref ref-type="bibr" rid="bibr16-0272989X12451058">16</xref><xref ref-type="bibr" rid="bibr17-0272989X12451058"/><xref ref-type="bibr" rid="bibr18-0272989X12451058"/><xref ref-type="bibr" rid="bibr19-0272989X12451058"/><xref ref-type="bibr" rid="bibr20-0272989X12451058"/><xref ref-type="bibr" rid="bibr21-0272989X12451058"/><xref ref-type="bibr" rid="bibr22-0272989X12451058"/><xref ref-type="bibr" rid="bibr23-0272989X12451058"/><xref ref-type="bibr" rid="bibr24-0272989X12451058"/><xref ref-type="bibr" rid="bibr25-0272989X12451058"/>–<xref ref-type="bibr" rid="bibr26-0272989X12451058">26</xref></sup> were found. Overall, these studies were small (mean = 42 patients per study). Data from these trials were linked within an evidence network and synthesized using Bayesian indirect and mixed treatment comparisons (IMTCs).<sup><xref ref-type="bibr" rid="bibr27-0272989X12451058">27</xref></sup> The analysis assumed a binomial likelihood. Relative, rather than absolute, measures of effectiveness were aggregated due to likely heterogeneity between trial populations. The binomial parameter of probability was described as a function of the absolute healing hazard, assuming a constant healing rate over time. Because most links in the network were informed by a single study and the number of healing events in some trials was small or zero, inferences on foam dressings were not obtained. Therefore, a common but random effect of any dressing treatment was initially assumed.<sup><xref ref-type="bibr" rid="bibr28-0272989X12451058">28</xref></sup> A more detailed description of the synthesis of relative effectiveness evidence is reported separately (see Appendix online). Results are presented in <xref ref-type="table" rid="table1-0272989X12451058">Table 1</xref> (column 1) as log hazard ratios with hydrocolloid as a reference treatment.</p>
</sec>
<sec id="section9-0272989X12451058">
<title>Costs and utilities</title>
<p>A broad literature search on health-related quality of life data yielded one publication<sup><xref ref-type="bibr" rid="bibr29-0272989X12451058">29</xref></sup> reporting Short Form-36 data from 218 people with and 2289 people without pressure ulceration (any grade) in the UK. Patient-level data from this study were used to calculate patient utility values (via the SF-6D<sup><xref ref-type="bibr" rid="bibr30-0272989X12451058">30</xref></sup>). To estimate mean utility in patients with and without pressure ulceration, a Bayesian linear regression was applied (adjusting for sex, age, and presence of comorbidities<sup><xref ref-type="bibr" rid="bibr29-0272989X12451058">29</xref></sup>). Results are presented in <xref ref-type="table" rid="table3-0272989X12451058">Table 3</xref> (column 1). The literature search of cost data yielded one relevant study.<sup><xref ref-type="bibr" rid="bibr31-0272989X12451058">31</xref></sup> The study did not collect primary data regarding the cost of treating severe pressure ulcers but rather developed treatment protocols that reflected good practice. Data from this study were used to derive weekly costs incurred by patients with an unhealed, severe pressure ulcer with and without complications (<xref ref-type="table" rid="table3-0272989X12451058">Table 3</xref>, column 1).</p>
<p>Despite the literature reviews being conducted by defining broad search criteria, we did not find evidence on the impact of complications, closure surgery, and recurrence in UK patients with pressure ulcers or on the impact of severe pressure ulceration on death. Standard UK life table data were used to describe mortality.<sup><xref ref-type="bibr" rid="bibr32-0272989X12451058">32</xref>,<xref ref-type="bibr" rid="bibr33-0272989X12451058">33</xref></sup></p>
</sec>
</sec>
<sec id="section10-0272989X12451058">
<title>Elicited Evidence</title>
<p>The existing evidence base on the treatments assessed was sparse; however, NPWT and comparators are used extensively within the NHS. Excluding such experience could misrepresent the current level of knowledge regarding these treatments. Thus, a formal exercise was designed to systematically capture experts’ knowledge and uncertainty around the treatment and progression of severe pressure ulcers; evidence was collected in the form of probabilistic judgments around various quantities.<sup><xref ref-type="bibr" rid="bibr34-0272989X12451058">34</xref></sup> A detailed report of the methods used in this elicitation exercise is published elsewhere.<sup><xref ref-type="bibr" rid="bibr8-0272989X12451058">8</xref></sup></p>
<p>As literature searches identified only limited existing data with which to characterize model transitions regarding healing rates and other relevant events, these quantities along with their uncertainty were elicited. While the elicitation methods would also have been appropriate for the collection of utilities, resource use, and costs data, the collection of these in addition to transition and related events was anticipated to be too arduous for experts given the available time and was not undertaken.</p>
<p>Because experts are unlikely to be able to specify nonobservable quantities reliably<sup><xref ref-type="bibr" rid="bibr2-0272989X12451058">2</xref></sup> (e.g., hazard of healing), we only elicited observable quantities<sup><xref ref-type="bibr" rid="bibr35-0272989X12451058">35</xref>,<xref ref-type="bibr" rid="bibr36-0272989X12451058">36</xref></sup> (e.g., proportion of patients healed): the exercise elicited all responses as proportions. It was thus anticipated that further parameterization (i.e., transformation) would be required for inclusion in the DAM. The data capture method used was the histogram method, which has been previously used in health technology assessment.<sup><xref ref-type="bibr" rid="bibr37-0272989X12451058">37</xref>,<xref ref-type="bibr" rid="bibr38-0272989X12451058">38</xref></sup></p>
<p>A sample of nurses with experience and knowledge of tissue viability and wound management were invited to participate in the exercise; they were also asked to invite colleagues with experience in treating pressure ulcers. In total, 23 nurses participated. The exercise was undertaken using a specially designed Microsoft Office Excel 2007 program (Redmond, WA). It was led by an experienced facilitator and included an extensive training session. A mathematical, rather than a consensus, approach was adopted,<sup><xref ref-type="bibr" rid="bibr2-0272989X12451058">2</xref></sup> requiring separate elicitation from each expert, with results from experts combined (linear pooling was used) after elicitation. The choice of the mathematical approach was based on a prior pilot exercise where beliefs were elicited using both mathematical and consensus methods. In this pilot, the consensus method (where experts were encouraged to interact to achieve a level of agreement for a particular parameter<sup><xref ref-type="bibr" rid="bibr39-0272989X12451058">39</xref></sup>) produced more accurate responses but also generated incoherent probability statements between 2 related quantities. These results are in line with the general view that consensus promotes the use of heuristics and may produce overconfident judgments.<sup><xref ref-type="bibr" rid="bibr40-0272989X12451058">40</xref></sup> To the pooled empiric distribution obtained after eliciting, parametric distributions were fitted using the method of moments. Results of the elicitation exercise for transition parameters and other relevant events (pooled discretized distribution, fitted distribution, and summary measures) are shown in <xref ref-type="table" rid="table1-0272989X12451058">Tables 1</xref> and <xref ref-type="table" rid="table2-0272989X12451058">2</xref> (column 2), respectively.</p>
</sec>
<sec id="section11-0272989X12451058">
<title>Pilot Trial–Derived Evidence</title>
<p>The third source of evidence was a pilot RCT. This pilot was conducted to generate further data and evaluate the feasibility of conducting large-scale primary research. It took place in one UK community health care trust and in one hospital. Patients were screened for eligibility during a 12-month recruitment period starting in September 2008. Consenting participants with grade 3 or 4 pressure ulcers were randomized to receive either NPWT (Vacuum Assisted Closure, Kinetic Concepts Inc., San Antonio, TX) or standard care (spun hydrocolloid, alginate, or foam dressings). Patients were followed up for 6 months. Twelve patients were recruited (6 per arm). The design of the trial was also tailored to collect data that would contribute to the DAM: data were collected on recruitment rates; occurrence of important events relevant to the model including complications, healing, and death; treatment changes and number of dressing changes; and EQ-5D. Data are presented descriptively in <xref ref-type="table" rid="table1-0272989X12451058">Tables 1</xref>, <xref ref-type="table" rid="table2-0272989X12451058">2</xref>, and <xref ref-type="table" rid="table3-0272989X12451058">3</xref> (column 4).</p>
</sec>
</sec>
<sec id="section12-0272989X12451058">
<title>Incorporating all Available Evidence</title>
<p>This section details how the 3 alternative sources of evidence were combined, followed by a description of the evidence and how this was used in the decision model (parameterization from the evidence). Evidence is presented for 3 sets of model parameters: parameters regarding transitions (speed at which healing or death occurs), other relevant events (complications and closure surgery), and costs and utilities.</p>
<sec id="section13-0272989X12451058">
<title>Collating the Sources of Evidence</title>
<p>The impact of each source of evidence on cost-effectiveness was evaluated by considering 3 scenarios: 1) existing evidence used alone, 2) existing evidence combined with elicited evidence, and 3) the most comprehensive evidence base that combined data from all 3 sources. The collation of evidence sources, necessary to generate the second and third scenarios, required Bayesian updating.<sup><xref ref-type="bibr" rid="bibr41-0272989X12451058">41</xref></sup> This was a 2-step procedure (illustrated in <xref ref-type="fig" rid="fig2-0272989X12451058">Figure 2</xref> using hypothetical distributions):</p>
<fig id="fig2-0272989X12451058" position="float">
<label>Figure 2</label>
<caption>
<p>Illustration of the 2-step procedure based on Bayesian updating used to generate alternative evidence scenarios.</p>
</caption>
<graphic xlink:href="10.1177_0272989X12451058-fig2.tif"/>
</fig>
<list id="list1-0272989X12451058" list-type="simple">
<list-item><p>Step 1: Elicited evidence was used as prior distribution (EL) and combined with data from existing evidence (EX) to generate the posterior density EX + EL; it is this posterior density that is further used in scenario 2 above.</p></list-item>
<list-item><p>Step 2: The posterior density from step 1 (EX + EL) was here considered prior distribution and was combined with trial-derived data (TR) to generate the posterior density EX + EL + TR. This posterior density collates all 3 sources of evidence and was used in scenario 3 above.</p></list-item>
</list>
<p>For existing and elicited evidence, the availability of data from these 2 sources conditioned how the data were collated. For all parameters except relative treatment effects, where only one evidence source was available, this alone was used to describe the parameter of interest. In estimating relative treatment effects, if no elicited evidence existed, Bayesian updating was used with vague or uninformative distributions as prior distribution. If both sources were available, expert opinion was considered subjective prior distribution and was combined with existing data to obtain inferences. When elicited prior data were included in the IMTC model, treatment effects could be estimated for each dressing individually.</p>
<p>The scenario collating all 3 sources of evidence (existing, elicited, and pilot trial derived) was also generated using Bayesian updating: posterior distributions derived from the collation of existing and elicited evidence were considered as priors distribution and updated with data from the pilot trial, where available.</p>
</sec>
<sec id="section14-0272989X12451058">
<title>Evidence on Transitions</title>
<p>All 3 sources of evidence provided data on healing. <xref ref-type="table" rid="table1-0272989X12451058">Table 1</xref> summarizes the available evidence using probability density functions for existing and elicited data (columns 1 and 2, respectively) and the data from the pilot trial (column 3). Existing and elicited evidence on relative treatment effects showed wide credible intervals (the Bayesian equivalent of confidence intervals), reflecting current uncertainties. The only marked difference between data sources was for foam dressings, which elicited expert opinion judged less effective than existing evidence indicated. The synthesis of existing RCT evidence required an assumed common but random effect of dressings. However, the elicited data allowed treatment effects to be estimated for each dressing individually, reflecting experts’ opinions. Overall, the inclusion of data from the pilot trial was not influential due to its small sample size and the fact that only one participant healed. Death data were obtained from UK life tables and updated with pilot trial, but not elicited, data (results not shown).</p>
<sec id="section15-0272989X12451058">
<title>Parameterizing the evidence</title>
<p>Consider that transition rates for patients treated with spun hydrocolloid dressing are denoted by <inline-formula id="inline-formula14-0272989X12451058"><mml:math display="inline" id="math14-0272989X12451058"><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, where the indexes <inline-formula id="inline-formula15-0272989X12451058"><mml:math display="inline" id="math15-0272989X12451058"><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula id="inline-formula16-0272989X12451058"><mml:math display="inline" id="math16-0272989X12451058"><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> indicate, respectively, the departure and arrival state (1 = unhealed; 2 = healed; 3 = dead) (<xref ref-type="fig" rid="fig1-0272989X12451058">Figure 1</xref>).</p>
<p>Inferences over transition parameters were obtained by assuming a continuous time evolvement, and hazard rates were estimated from the data (<xref ref-type="table" rid="table1-0272989X12451058">Table 1</xref>). Despite parameters being estimated in continuous time, a discretized version of the Markov model was used to establish cost-effectiveness. Transition probabilities for a prespecified cycle length, <inline-formula id="inline-formula17-0272989X12451058"><mml:math display="inline" id="math17-0272989X12451058"><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, needed to be evaluated from the corresponding transition rates. For the 3 state models, the solution to the Kolmogorov equations<sup><xref ref-type="bibr" rid="bibr42-0272989X12451058">42</xref></sup> regarding the unknown probability transition parameters is</p>
<p>
<disp-formula id="disp-formula1-0272989X12451058">
<mml:math display="block" id="math18-0272989X12451058">
<mml:mrow>
<mml:mrow>
<mml:mo>{</mml:mo>
<mml:mtable align="left">
<mml:mtr>
<mml:mtd columnalign="left">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>11</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msup>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>13</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>·</mml:mo>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:msup>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>·</mml:mo>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>·</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>13</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>·</mml:mo>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>12</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>13</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd columnalign="left" columnspan="1">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>22</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mo>=</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msup>
<mml:mrow>
<mml:mi>e</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>23</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>·</mml:mo>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X12451058" xlink:href="10.1177_0272989X12451058-eq1.tif"/>
</disp-formula>
</p>
<p>The rates of death for healed and unhealed patients were assumed equal, <inline-formula id="inline-formula18-0272989X12451058"><mml:math display="inline" id="math19-0272989X12451058"><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>23</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, and therefore, the probability of healing in a certain period of time was simplified to <inline-formula id="inline-formula19-0272989X12451058"><mml:math display="inline" id="math20-0272989X12451058"><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>13</mml:mn></mml:mrow></mml:msub><mml:mo>·</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>·</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. Available trial evidence was used to estimate the rates; however, most trials disregarded individuals who died when reporting healing outcomes. Consequently, these trials reported the probability that a patient heals is conditional on not having died. This quantity equates to <inline-formula id="inline-formula20-0272989X12451058"><mml:math display="inline" id="math21-0272989X12451058"><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>·</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> when death rates are assumed to be equal for healed and unhealed patients. This functional relation was used in the synthesis of available evidence to aggregate the outcomes of the distinct trials (see Appendix online).</p>
<p>It was assumed that the treatments being evaluated would impact healing; their effectiveness was parameterized as a treatment effect relative to spun hydrocolloid dressings (hazard ratios). After 6 months unhealed, patients were assumed to have a different rate of healing, informed by expert opinion only (<xref ref-type="table" rid="table1-0272989X12451058">Table 1</xref>). Given there is no evidence regarding the effectiveness of treatments after 6 months, treatments were assumed not to impact the rate of healing.</p>
</sec>
</sec>
<sec id="section16-0272989X12451058">
<title>Evidence on Relevant Events</title>
<p>Relevant events were the occurrence and resolution of complications related to severe pressure ulceration (osteomyelitis or systemic infection), occurrence and success of closure surgery in the UK, and discontinuation of treatments. As no UK data were identified from the literature regarding these events, they were elicited. In general, experts expressed substantial uncertainty regarding these parameters, possibly reflecting their lack of direct experience (<xref ref-type="table" rid="table2-0272989X12451058">Table 2</xref>, distribution (3)). The pilot trial evidence had a significant impact on those estimates where elicited data were very uncertain (<xref ref-type="table" rid="table2-0272989X12451058">Table 2</xref>, distribution (5)); for example, trial data suggested that the duration of treatment was much shorter than assumed under existing evidence. No complications occurred during pilot trial follow-up.</p>
<sec id="section17-0272989X12451058">
<title>Parameterizing the evidence</title>
<p>Complications and discontinuation of treatment occur only in unhealed patients. Thus, a measure of the incidence of these events was applied to the pool of unhealed patients at each time interval of the Markov model. Complications were allowed to differ by treatment type.</p>
<p>Classifying a closure surgery as “successful” meant that an ulcer was considered healed. This required further consideration because uncertain judgments obtained from expert opinion regarding the occurrence and success of closure surgery had the potential to generate probabilistically incoherent results regarding healing. To prevent this, a different parameterization was adopted, and 2 alternative quantities (quantities 1 and 2 as defined in <xref ref-type="table" rid="table2-0272989X12451058">Table 2</xref>) were considered for inclusion in the model: <inline-formula id="inline-formula21-0272989X12451058"><mml:math display="inline" id="math22-0272989X12451058"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and <inline-formula id="inline-formula22-0272989X12451058"><mml:math display="inline" id="math23-0272989X12451058"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, where <italic>S</italic> is the occurrence of closure surgery and <italic>H</italic> is the occurrence of healing. These quantities were used, alongside the overall probability of healing, to determine the occurrence of closure surgery by using the relation <inline-formula id="inline-formula23-0272989X12451058"><mml:math display="inline" id="math24-0272989X12451058"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mi>S</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>H</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mo>·</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mi>H</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>.</p>
</sec>
</sec>
<sec id="section18-0272989X12451058">
<title>Evidence on Costs and Utilities</title>
<p>Costs and resource use data were derived from the literature,<sup><xref ref-type="bibr" rid="bibr31-0272989X12451058">31</xref></sup> with diffuse distributions assigned to reported point estimates (<xref ref-type="table" rid="table2-0272989X12451058">Table 2</xref>). No cost or utility data were elicited. The data derived from the pilot trial were influential in describing these uncertain quantities, that is, for the number of dressing changes for NPWT and comparator dressing treatments. Utilities for unhealed patients were estimated from the available data set and updated with pilot trial–derived EQ-5D scores (<xref ref-type="table" rid="table3-0272989X12451058">Table 3</xref>). Utilities for unhealed patients in the trial were substantially lower (mean = 0.110) than values derived from the literature (mean = 0.660). However, because of its small sample size, trial-derived utility data did not have a significant impact on the posterior distribution. These parameters were applied directly to the model; no further parameterization was conducted.</p>
</sec>
<sec id="section19-0272989X12451058">
<title>Nonstochastic Parameters</title>
<p>Other model parameters, mainly unit costs, were assumed to be nonstochastic (<xref ref-type="table" rid="table4-0272989X12451058">Table 4</xref>). Unit cost parameters were derived from national figures. The incidence and prevalence of severe pressure ulcers were used in calculating the value of conducting further research.</p>
<table-wrap id="table4-0272989X12451058" position="float">
<label>Table 4</label>
<caption>
<p>Nonstochastic Parameters</p>
</caption>
<graphic alternate-form-of="table4-0272989X12451058" xlink:href="10.1177_0272989X12451058-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Description</th>
<th align="center">Value</th>
<th align="center">Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatments, cost (£)</td>
<td/>
<td/>
</tr>
<tr>
<td> NPWT</td>
<td/>
<td/>
</tr>
<tr>
<td>  Cost of VAC machine and canister, £/week</td>
<td>£299</td>
<td/>
</tr>
<tr>
<td>  Cost of VAC dressings, £/dressing change</td>
<td>£25.49</td>
<td/>
</tr>
<tr>
<td> Foam, £/dressing change</td>
<td>£3.79</td>
<td/>
</tr>
<tr>
<td> Alginate, £/dressing change</td>
<td>£2.10</td>
<td/>
</tr>
<tr>
<td> Spun hydrocolloid, £/ dressing change</td>
<td>£2.48</td>
<td/>
</tr>
<tr>
<td>Other unit costs</td>
<td/>
<td/>
</tr>
<tr>
<td> Costs associated with treatment change excluding treatments (additional dressing costs), £/dressing change</td>
<td>£21.19</td>
<td>Bennett and others<sup><xref ref-type="bibr" rid="bibr31-0272989X12451058">31</xref></sup>
</td>
</tr>
<tr>
<td> Costs of closure surgery, £/surgery</td>
<td>£2795.72</td>
<td>Department of Health<sup><xref ref-type="bibr" rid="bibr51-0272989X12451058">51</xref></sup>
</td>
</tr>
<tr>
<td>Other parameters</td>
<td/>
<td/>
</tr>
<tr>
<td> Resident population of the UK (mid-2008)</td>
<td>61,383,000</td>
<td>Office for National Statistics<sup><xref ref-type="bibr" rid="bibr33-0272989X12451058">33</xref></sup></td>
</tr>
<tr>
<td> Prevalence of pressure ulceration, per 1000 individuals</td>
<td>0.74</td>
<td>Vowden and Vowden<sup><xref ref-type="bibr" rid="bibr52-0272989X12451058">52</xref></sup></td>
</tr>
<tr>
<td> Proportion of severe ulcers out of total ulcers</td>
<td>33%</td>
<td>Vowden and Vowden<sup><xref ref-type="bibr" rid="bibr52-0272989X12451058">52</xref></sup></td>
</tr>
<tr>
<td> Incidence of severe ulcers</td>
<td>4997 cases/year<sup><xref ref-type="table-fn" rid="table-fn12-0272989X12451058">a</xref></sup></td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0272989X12451058">
<p>Note: NPWT = negative-pressure wound therapy; VAC = vacuum assisted closure.</p>
</fn>
<fn id="table-fn12-0272989X12451058">
<label>a.</label>
<p>The estimate of 4997 incident cases per year was based on the total population of the UK and on the incidence of severe pressure ulceration. The latter derived from the prevalence of pressure ulceration, the proportion of grade 3 and 4 pressure ulcers, and the expected time to healing of a pressure ulcer (61,383,000 × 0.74/1000 × 0.33 / 3 years = 14,990 / 3 years = 4997, discounted at 3.5% as 1/(1 + 0.035)^(time in years – 1).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section20-0272989X12451058">
<title>Cost-Effectiveness and Decision Uncertainty</title>
<p>The model was run probabilistically using 1000 Monte Carlo simulations. The number of simulations was defined using assessments of convergence.</p>
<sec id="section21-0272989X12451058">
<title>Cost-Effectiveness Based on Existing Evidence Alone (Scenario 1)</title>
<p>In <xref ref-type="fig" rid="fig3-0272989X12451058">Figure 3A</xref>, where cost-effectiveness calculations were informed by data from existing literature, foam appeared to be the most effective dressing treatment. This finding was, however, attributed to the assumption of common (random) effects employed for the synthesis of existing trial data. In this scenario, NPWT does not appear cost-effective: it had the lowest expected NHB (<xref ref-type="fig" rid="fig3-0272989X12451058">Figure 3A</xref>). If treatment choice was based on existing data (combined with the necessary assumptions), then foam dressings might be recommended. However, such a decision would be highly uncertain (<italic>P</italic> = 0.32 of being cost-effective), and it would be very likely that any of the other treatments might offer similar or better value (<italic>P</italic> = 0.16 for spun hydrocolloid dressings, 0.30 for alginate dressings, and 0.22 for NPWT).</p>
<fig id="fig3-0272989X12451058" position="float">
<label>Figure 3</label>
<caption>
<p>Cost-effectiveness and decision uncertainty considering existing evidence (A), existing and elicited evidence (B), and existing, elicited, and trial-derived evidence (C). For each scenario, cost-effectiveness planes are presented on the left and expected net benefit plotted against the probability of each of the treatments being cost-effective at a willingness to pay of £20,000/QALY on the right. NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; NHB = net health benefit; QALY = quality-adjusted life year.</p>
</caption>
<graphic xlink:href="10.1177_0272989X12451058-fig3.tif"/>
</fig>
</sec>
<sec id="section22-0272989X12451058">
<title>Cost-Effectiveness Based on Existing and Elicited Evidence (Scenario 2)</title>
<p>Analysis based on combined existing and elicited data suggested that spun hydrocolloid dressing had the highest expected NHB (<xref ref-type="fig" rid="fig3-0272989X12451058">Figure 3B</xref>). The inclusion of elicited evidence, which suggested that foam dressings were the least effective treatment, meant that this treatment was very unlikely to be cost-effective (<italic>P</italic> = 0.02). Again, NPWT was estimated to be more effective than the dressing comparators. Uncertainty in choosing the optimal treatment was also substantial in this scenario (<italic>P</italic> = 0.37 for spun hydrocolloid dressings, 0.32 for alginate dressings, and 0.29 for NPWT).</p>
</sec>
<sec id="section23-0272989X12451058">
<title>Cost-Effectiveness Based on Existing, Elicited, and Pilot Trial–Derived Evidence (Scenario 3)</title>
<p>When all evidence sources were combined, NPWT was expected to be less costly and more effective than other treatments (<xref ref-type="fig" rid="fig3-0272989X12451058">Figure 3C</xref>). This suggests that this treatment could be adopted for the treatment of severe pressure ulcers (<xref ref-type="table" rid="table5-0272989X12451058">Table 5</xref>). The improved cost-effectiveness of NPWT reflected the shorter duration of treatment in the pilot trial than that reported by manufacturers and with fewer dressing changes. However, even using all available evidence, a decision is still very uncertain (<xref ref-type="table" rid="table5-0272989X12451058">Table 5</xref>); there is a significant chance (approximately 0.55) that NPWT will in fact not offer the best value.</p>
<table-wrap id="table5-0272989X12451058" position="float">
<label>Table 5</label>
<caption>
<p>Cost-Effectiveness Estimates When Existing, Elicited, and Pilot Trial Evidence Are Considered</p>
</caption>
<graphic alternate-form-of="table5-0272989X12451058" xlink:href="10.1177_0272989X12451058-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th/>
<th/>
<th/>
<th align="center" colspan="2">Probability of a Treatment Being Cost-Effective<hr/></th>
</tr>
<tr>
<th align="left">Treatment</th>
<th align="center">Costs (£)</th>
<th align="center">Effectiveness (QALY)</th>
<th align="center">NHB (QALY)</th>
<th align="center">Next Best ICER (£/QALY)</th>
<th align="center">£20,000</th>
<th align="center">£30,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPWT</td>
<td>10,399</td>
<td>1.273</td>
<td>0.754</td>
<td align="center">—</td>
<td>0.451</td>
<td>0.460</td>
</tr>
<tr>
<td>HC</td>
<td>13,461</td>
<td>1.264</td>
<td>0.591</td>
<td>Dominated</td>
<td>0.304</td>
<td>0.296</td>
</tr>
<tr>
<td>ALG</td>
<td>14,898</td>
<td>1.261</td>
<td>0.516</td>
<td>Dominated</td>
<td>0.230</td>
<td>0.231</td>
</tr>
<tr>
<td>F</td>
<td>18,969</td>
<td>1.254</td>
<td>0.305</td>
<td>Dominated</td>
<td>0.015</td>
<td>0.013</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn13-0272989X12451058">
<p>Note: NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; NHB = net health benefit; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life year.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section24-0272989X12451058">
<title>Value of Further Research</title>
<p>All available evidence was used to conduct a value of further research analysis. Before presenting the results of these analyses, specificities to their implementation are detailed.</p>
<sec id="section25-0272989X12451058">
<title>Implementation of EVPI Analysis</title>
<p>Estimates of the EVPI for subsets of parameters require that these parameters are not correlated with the remaining model parameters. Given that relative treatment effects were estimated jointly, the existence and impact of correlation were assessed prior to implementing the EVPI analyses. For such, correlation between the estimated log hazard ratios and between transformations of these parameters (as used in the decision model) was assessed using correlation coefficients and graphical displays (scatterplots): there was no indication of the presence of correlation between the input parameters. We also evaluated the potential impact of correlation in the outcomes: 1) in the NHBs associated with the treatments, 2) in the decision regarding which treatment to adopt, and 3) in the maximum NHBs attained. We used only graphical methods to evaluate item 1: distinct values of a conditioning parameter (1 of the 3 treatment effect parameters) were plotted against the NHBs associated with the remaining treatments. This was applied in turn to all 3 treatment effects. To evaluate the impact over the adoption decision (item 2 above) for distinct quartiles of the conditioning parameter, the probabilities that the remaining treatments were chosen as the optimum treatment were evaluated. These were not expected to differ significantly between the quartiles. To evaluate the impact over maximum net benefits (item 3 above) for each quartile of the variable of interest, we summarized the maximum net benefits. These were again not expected to differ significantly. The results did not show correlation to have a significant impact, and independence was therefore assumed, allowing parameter EVPI to be estimated separately for each treatment effect parameter.</p>
<p>We also note that in calculating parameter EVPI, model linearity was not assumed, and 2 nested Monte Carlo simulation procedures were conducted to evaluate the nested expectations. Convergence was assessed, and 1000 simulations were used in both simulation procedures.</p>
</sec>
<sec id="section26-0272989X12451058">
<title>Results of EVPI Analysis</title>
<p>The EVPI for the choice between NPWT and the dressing treatments was estimated to be 0.114 QALYs per patient or £2273, which represents the monetary value of resolving the uncertainty surrounding treatment choice for each patient (<xref ref-type="table" rid="table6-0272989X12451058">Table 6</xref>). The incident UK population of grade 3 or 4 pressure ulcer patients was estimated at 4997 per year (<xref ref-type="table" rid="table4-0272989X12451058">Table 4</xref>), and assuming benefits from research would last 10 years, the EVPI for this population of patients was approximately £97.8 million. This represents the maximum value of further research that might resolve existing uncertainties. Because this value exceeds the likely costs of further investigation, additional research in this area is potentially worthwhile.</p>
<table-wrap id="table6-0272989X12451058" position="float">
<label>Table 6</label>
<caption>
<p>Estimates of the Value of Further Research</p>
</caption>
<graphic alternate-form-of="table6-0272989X12451058" xlink:href="10.1177_0272989X12451058-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Individual Value: NHB, QALY (NMB, £)</th>
<th align="center">Population Values<sup><xref ref-type="table-fn" rid="table-fn15-0272989X12451058">a</xref></sup>: NHB, QALY (NMB, £)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVPI</td>
<td>0.114 (£2273)</td>
<td>4888 (£97.8 million)</td>
</tr>
<tr>
<td>EVPI for transition parameters</td>
<td/>
<td/>
</tr>
<tr>
<td> Absolute healing parameters and death rates</td>
<td>0 (£0)</td>
<td>0 (£0)</td>
</tr>
<tr>
<td> Relative treatment effects</td>
<td>0.101 (£2010)</td>
<td>4327 (£87 million)</td>
</tr>
<tr>
<td>  F v. HC</td>
<td>0.001 (£13)</td>
<td>29 (£0.6 million)</td>
</tr>
<tr>
<td>  ALG v. HC</td>
<td>0.041 (£817)</td>
<td>1757 (£35.1 million)</td>
</tr>
<tr>
<td>  NPWT v. HC</td>
<td>0.056 (£1114)</td>
<td>2395 (£47.9 million)</td>
</tr>
<tr>
<td>EVPI for other relevant events and payoffs</td>
<td/>
<td/>
</tr>
<tr>
<td> Related events (surgery and complications)</td>
<td>0 (£0)</td>
<td>0 (£0)</td>
</tr>
<tr>
<td> Costs, discontinuation, and number of dressing changes</td>
<td>0.018 (£363)</td>
<td>780 (£15.6 million)</td>
</tr>
<tr>
<td> Utilities</td>
<td>0 (£0)</td>
<td>0 (£0)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn14-0272989X12451058">
<p>Note: NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; NHB = net health benefit; NMB = net monetary benefit; EVPI = expected value of perfect information; QALY = quality-adjusted life year.</p>
</fn>
<fn id="table-fn15-0272989X12451058">
<label>a.</label>
<p>Benefits from research are assumed to sustain for 10 years.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the case study, the EVPI associated with the relative effectiveness parameters, specifically for NPWT and alginate dressing compared with spun hydrocolloid dressing, was estimated to be £83 million, suggesting that investment in an RCT to provide unbiased estimates of these parameters might be worthwhile. However, additional evidence about cost parameters might also be valuable because they were associated with an EVPI of £15.6 million. The analyses suggested that there was little value associated with resolving uncertainties in the other parameters, such as utilities, and baseline progression.</p>
</sec>
</sec>
<sec id="section27-0272989X12451058">
<title>Design of Further Research</title>
<p>In the analyses of parameter EVPI, uncertainty over the relative effectiveness parameters was identified to have the highest consequences; we have thus taken this forward by evaluating the EVSI, focusing on the design of an RCT.</p>
<sec id="section28-0272989X12451058">
<title>Research Designs Evaluated</title>
<p>The EVSI associated with 3 alternative trial designs was established: 1) a 2-arm trial evaluating NPWT versus spun hydrocolloid dressings, 2) a 2-arm trial evaluating NPWT versus alginate dressings, and 3) a 3-arm trial evaluating the 3 treatments. In the case study, primary research results were assumed to inform the relative treatment effect but not the baseline hazard. For each trial design, the sample size of each arm was assumed equal.</p>
<p>Within the framework of analyses implemented, the outcomes measured within a future trial were numbers of patients achieving healing (the data mentioned in the previous section on the analytic framework). This quantity was modeled using a Poisson variable where a given sample size and follow-up period need to be assumed, an approach that is proposed by Ades and others<sup><xref ref-type="bibr" rid="bibr12-0272989X12451058">12</xref></sup> in calculating the EVSI for hazard ratios using conjugacy. In the case study, a range of sample sizes and the impact of alternative follow-up times (i.e., duration of data collection for each participant after randomization) of 0.5, 1, and 2 years were also evaluated. Given a Poisson distribution is used, the rate of occurrence of these events is assumed constant with exposure, where exposure combines sample size with follow-up time. A study with, for example, 200 patients followed up for 0.5 years thus provides the same information as a study with 100 patients but with a follow-up time of 1 year.</p>
<p>Predictions of the costs of possible research designs were based on those of previously funded wound care projects (<xref ref-type="table" rid="table7-0272989X12451058">Table 7</xref>). Potential recruitment rates (1 patient per month/site) and staffing levels required were based on data from the pilot study, where recruitment occurred at a low rate.</p>
<table-wrap id="table7-0272989X12451058" position="float">
<label>Table 7</label>
<caption>
<p>Breakdown of Assumed Annual Costs for a Future Trial</p>
</caption>
<graphic alternate-form-of="table7-0272989X12451058" xlink:href="10.1177_0272989X12451058-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Annual Cost</th>
<th align="center">Phase of Study Where Annual Cost Is Incurred</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site staff</td>
<td/>
<td/>
</tr>
<tr>
<td>Principal investigator</td>
<td>£2389.8 per site</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Research nurse</td>
<td>£33,727 per site</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Treating nurse</td>
<td>£516.18 per patient</td>
<td>Recruitment and follow-up</td>
</tr>
<tr>
<td>Site administrator</td>
<td>£698.04 per site</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>University staff</td>
<td/>
<td/>
</tr>
<tr>
<td>Chief investigator</td>
<td>£4926.45</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Senior statistician</td>
<td>£4926.45</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Junior statistician</td>
<td>£14,370.8</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Health economist</td>
<td>£14,370.8</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Methodologist</td>
<td>£4926.45</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Trial coordinator</td>
<td>£35,927</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Administrative staff</td>
<td>£5085</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Data management</td>
<td>£12,944.2</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Excess treatment costs</td>
<td>£3232 per patient</td>
<td/>
</tr>
<tr>
<td>Other consumables</td>
<td>£12,000</td>
<td>Recruitment, start-up, and follow-up</td>
</tr>
<tr>
<td>Overheads</td>
<td/>
<td>70% of costs with research staff at university</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section29-0272989X12451058">
<title>Implementation of EVSI and ENBS Analysis</title>
<p>Calculations of the EVSI assume that prior information is updated using the data made available to generate the posterior distribution <inline-formula id="inline-formula24-0272989X12451058"><mml:math display="inline" id="math25-0272989X12451058"><mml:mrow><mml:mrow><mml:mi>υ</mml:mi><mml:mo>|</mml:mo></mml:mrow><mml:mi>data</mml:mi></mml:mrow></mml:math></inline-formula>. This requires Bayesian updating; conjugacy was used (the prior distribution and data are conjugate distributions), and thus, the posterior distribution was known in closed form.</p>
<p>Despite this, the computational burden of estimating the EVSI for all research designs without assuming linearity would have been significant (7.5 days to evaluate 20 alternative sample sizes). Linearity can be assumed when the model outputs (here, the NHBs) are a linear (or multilinear under certain additional conditions<sup><xref ref-type="bibr" rid="bibr12-0272989X12451058">12</xref></sup>) function of the input parameters (<inline-formula id="inline-formula25-0272989X12451058"><mml:math display="inline" id="math26-0272989X12451058"><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:math></inline-formula>). Assuming linearity means expected NHBs can be computed in a single calculation with the parameters set to their expected values (because <inline-formula id="inline-formula26-0272989X12451058"><mml:math display="inline" id="math27-0272989X12451058"><mml:mrow><mml:munder><mml:mrow><mml:mtext>E</mml:mtext></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>θ</mml:mi></mml:mrow></mml:msubsup><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> is equal to <inline-formula id="inline-formula27-0272989X12451058"><mml:math display="inline" id="math28-0272989X12451058"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>NHB</mml:mtext></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>E</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>). In practice, 1 of the 2 nested simulation procedures needed for computations of parameter EVPI and EVSI can be eliminated, reducing significantly the computational burden.</p>
<p>Within this work, the extent and impact of nonlinearity were evaluated by comparing the results of nonlinear computations (for parameter EVPI) with those based on an assumption of linearity. Results were similar between approaches, and thus, linearity was used to obtain a first estimate of optimal sample size (N*) for each trial design. To confirm the linear estimate of the sample size leading to the maximum ENBS, nonlinear ENBS estimates were obtained for N* and for sample sizes representing ±20% of N*. For all alternative designs evaluated, the value of the ENBS calculated nonlinearly was similar to the one calculated linearly and confirmed the estimate of N*.</p>
<p>A second consideration in calculating the EVSI is correlation, and following the results of investigations undertaken for parameter EVPI in the case study, independence was assumed throughout. Convergence was evaluated for all simulation procedures and was used to define the number of samples with which to conduct the EVSI (1000 for each simulation procedure).</p>
</sec>
<sec id="section30-0272989X12451058">
<title>Results of EVSI and ENBS Analysis</title>
<p>The results of EVSI analysis indicate that, across distinct sample sizes, a 3-arm trial would produce more value than a 2-arm trial (EVSI in <xref ref-type="fig" rid="fig4-0272989X12451058">Figure 4</xref>). Within 2-arm trials, comparing NPWT with alginate dressings was of more value than comparing with spun hydrocolloid dressings (due to the higher uncertainty regarding the use of alginate dressings).</p>
<fig id="fig4-0272989X12451058" position="float">
<label>Figure 4</label>
<caption>
<p>Population EVSI, costs of a trial, and ENBS for alternative designs of a randomized controlled trial of 1 year of follow-up: (A) two arm trial of NPWT v. HC, (B) two arm trial of NPWT v. ALG, (A) three arm trial of NPWT v. HC v. ALG. Vertical gray line represents the sample size at which the maximum ENBS is obtained. NPWT = negative-pressure wound therapy; HC = spun hydrocolloid; ALG = alginate; F = foam; EVSI = expected value of sample information; ENBS = expected net benefit of sampling.</p>
</caption>
<graphic xlink:href="10.1177_0272989X12451058-fig4.tif"/>
</fig>
<p>Trials following up patients for 0.5 years were shown to be less efficient research designs or not worthwhile (<xref ref-type="table" rid="table8-0272989X12451058">Table 8</xref>). Longer follow-up times provided the best value (higher ENBS); however, a trial considering a 2-year follow-up is likely to be difficult to implement in this patient population. <xref ref-type="table" rid="table8-0272989X12451058">Table 8</xref> shows that the maximum ENBS for a 3-arm trial with 1-year follow-up is reached at a sample size of 497 patients (in each arm), with an estimated net value of £34.7 million, while the maximum ENBS for a 2-arm trial (NPWT v. alginate dressings) is returned with a sample size of 306 patients, with a net value of £27.2 million.</p>
<table-wrap id="table8-0272989X12451058" position="float">
<label>Table 8</label>
<caption>
<p>Optimal Sample Size and ENBS for Alternative Designs of Further Research</p>
</caption>
<graphic alternate-form-of="table8-0272989X12451058" xlink:href="10.1177_0272989X12451058-table8.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">NPWT v. Spun Hydrocolloid<hr/></th>
<th align="center" colspan="2">NPWT v. Alginate<hr/></th>
<th align="center" colspan="2">NPWT v. Spun Hydrocolloid v. Alginate<hr/></th>
</tr>
<tr>
<th align="left">Follow-up Time</th>
<th align="center">Maximum ENBS</th>
<th align="center">Optimal Sample Size, N*</th>
<th align="center">Maximum ENBS</th>
<th align="center">Optimal Sample Size, N*</th>
<th align="center">Maximum ENBS</th>
<th align="center">Optimal Sample Size, N*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5 years</td>
<td align="center">—</td>
<td align="center">—</td>
<td>£12.3 million</td>
<td>272</td>
<td align="center">£154,028</td>
<td>403</td>
</tr>
<tr>
<td>1 year</td>
<td>£14.0 million</td>
<td>476</td>
<td>£27.2 million</td>
<td>306</td>
<td>£34.7 million</td>
<td>497</td>
</tr>
<tr>
<td>2 years</td>
<td>£27.1 million</td>
<td>389</td>
<td>£35.2 million</td>
<td>234</td>
<td>£54.6 million</td>
<td>411</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn16-0272989X12451058">
<p>Note: The maximum ENBS was calculated from smoothed ENBS functions using a polynomial function of degree 5. Smoothing did not provide a good fit in one scenario (3-arm trial following up patients for 0.5 years), in which case the observed maximum ENBS and correspondent sample size are presented. NPWT = negative-pressure wound therapy; ENBS = expected net benefit of sampling.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section31-0272989X12451058" sec-type="discussion">
<title>Discussion</title>
<p>This research demonstrates the use of explicit methods to estimate the cost-effectiveness of a range of treatments while characterizing the considerable uncertainty regarding treatment choice. The use of NPWT in severe pressure ulceration was utilized as a case study; this is a medical device widely used in the UK to treat these ulcers, despite a dearth of evidence regarding its relative effectiveness.</p>
<p>A key feature of this work is that multiple sources of available evidence were included in the evaluation in a transparent way: data from the literature (using IMTCs to estimate relative treatment effects in the absence of relevant head-to-head trials), elicited data, and pilot trial data. The presentation of cost-effectiveness estimates after the addition of data from each source into the model emphasizes how different conclusions would have been drawn if analysis were limited to only one source of data. This highlights the importance of including all relevant data in any DAM.<sup><xref ref-type="bibr" rid="bibr43-0272989X12451058">43</xref></sup></p>
<p>To collate the evidence from each of the sources, we used Bayesian updating. This methodology has the potential of being used sequentially, for example, in updating the results of DAMs every time new evidence becomes available. This can be extremely useful when 1) adoption and research decisions are linked, as the adoption decision needs to be revised after research reports, or 2) when research is conducted sequentially. An example of the latter could have been implemented in our case study because existing evidence alone could have been firstly used to establish the need for elicited evidence. This was not done (and all sources were collected without looking at the results of the DAM) because many parameters of the DAM had no evidence available in the literature and vague or uninformative distributions were thus used to describe these. In specifying these distributions, a judgment on the value of the mean is required, which can, as a consequence, affect cost-effectiveness and the valuation of further research needs.</p>
<p>One feature of the DAM implemented was that while it considered closure surgery and the occurrence of complications on healing, it did not explicitly evaluate the impact of these on healing rates. There was, however, an absence of data that suggests such a relationship. Additionally, studies in the literature evaluating the effectiveness of distinct treatments report the proportion of patients who have healed over time, but patients may have had complications or closure surgery before healing. Analytically, these data are identified as partially observed data.<sup><xref ref-type="bibr" rid="bibr42-0272989X12451058">42</xref></sup> Methods to adequately analyze these data are complex, and the computational burden increases with model complexity. A more complex model could thus have been specified; however, given the absence of evidence and the complexity of implementation, this was deemed unreasonable.</p>
<p>Another feature of the current analyses was that recurrence was not considered. We found no existing evidence to indicate that the alternative treatments impacted ulcer recurrence, and there is also no clinical rationale for an association. Even when assuming no impact of treatment on recurrence, if recurrence rates were high, cost-effectiveness may have been overestimated. This is because the time spent in the state healed would be inferior due to recurrence. Because there were only small differences in utility between healed and unhealed states, we would not expect this to have a significant impact on the results. Despite not having incorporated recurrence in the decision model (due to an expected increase in model complexity), we did elicit recurrence rates: the experts expected 31% of healed patients to have a recurrence after 6 months (SD = 24%), and 24% of patients were expected to have a recurrence in the following 6 months (SD = 22%). This was elicited using 2 questions: 1) Think of UK patients with at least one debrided grade 3 or 4 pressure ulcer (greater than 5 cm<sup>2</sup> in area). Imagine that these patients had their deepest grade 3 or 4 pressure ulcer (reference ulcer) treated and that it healed completely at some point. Six months after healing, what proportion of patients do you think would have a recurrent pressure ulcer (grade 2 to 4) in the same site as their previous grade 3 or 4 reference ulcer? 2) Now think of only those patients who still do not have a recurrent pressure ulcer 6 months after healing. What proportion of them do you think would have a recurrent pressure ulcer (grade 2 to 4) in the same site between 6 and 12 months after healing of the reference ulcer?</p>
<p>Previous assessments of cost-effectiveness in wound care evaluated decision models using both patient-level simulation<sup><xref ref-type="bibr" rid="bibr44-0272989X12451058">44</xref></sup> and cohort models.<sup><xref ref-type="bibr" rid="bibr45-0272989X12451058">45</xref></sup> In the case study, we used a discrete time cohort model because the use of a patient-level simulation model could have either precluded the analyses of the value of further research or it could have meant that a metamodel or other approximation needed to be used.<sup><xref ref-type="bibr" rid="bibr46-0272989X12451058">46</xref>,<xref ref-type="bibr" rid="bibr47-0272989X12451058">47</xref></sup></p>
<p>As well as facilitating immediate decision making, the results of this study suggest that the implications of continuing to use NPWT in the UK in the absence of robust evidence are likely to be even more costly than conducting further research to reduce the uncertainty. The value of further research analysis was possible when it was most important, that is, when the existing evidence base was clearly insufficient, and further research will need to be prioritized. In guiding further research, alternative study designs were evaluated, including not only the sample size of an RCT but also possible comparator arms and alternative follow-up times. By conducting a pilot trial, we were able to assess both the feasibility of future research and its likely costs (through, for example, prediction of recruitment rates). This information is invaluable to research commissioners often faced with the aftermath of unrealistic, anticipated recruitment rates and the high cost of study extensions.<sup><xref ref-type="bibr" rid="bibr48-0272989X12451058">48</xref></sup></p>
<p>A key source of data was the elicitation of clinical experience, and therefore, the conclusions drawn are to some extent dependent on the experts’ judgments. Ignoring experts’ beliefs as a source of evidence could be regarded as wasteful (which often translates into money).<sup><xref ref-type="bibr" rid="bibr49-0272989X12451058">49</xref></sup> Despite the elicitation used here, representing one of the largest exercises of its type to have been undertaken in the field of health technology assessment, performing such an extensive quantitative elicitation exercise required a number of assumptions, including independence between the quantities elicited by each expert. However, such assumptions are common in statistical or mathematical modeling.</p>
<p>When combining experimental and elicited evidence, it is important to consider the potential for double counting. Although there is no way to know how much the nurse experts have considered existing evidence when formulating their judgments, it is likely that their own experience was the main source. This is because published research evidence was very sparse, and results of IMTCs were not made available to them. Moreover, the treatments of interest were not divulged before the elicitation exercise, and nurses were not incentivized to review the existing literature.</p>
<p>The analyses presented here demonstrate how decisions about medical technologies can be explicitly informed when data are sparse and, most importantly, guiding future research prioritization, not only indicating whether further research is worthwhile but also what “kind” of research is needed and how it should be designed.</p>
</sec>
</body>
<back>
<ack>
<p>We thank all the nurses and tutors who took part in the pilot and full elicitation exercises and all the staff and patients involved in the pilot trial, especially research nurse Sally Blundell. We also thank Holly Essex and Mike Clark for supplying quality of life data and John Posnett for supplying data from a previous study he conducted. We also thank Tony Ades and Nicky Welton for analytical help and advice. The literature searches were carried out by Ruth Foxlee.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This work was supported by the Medical Research Council (grant number G0501814). Kinetic Concepts Inc. supplied the NPWT machines used in the pilot trial at no cost. The manufacturer had no role in the design of the pilot trial or in the collection, analysis, and interpretation of the data.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X12451058">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Drummond</surname><given-names>M</given-names></name>
</person-group>. <article-title>A rational framework for decision making by the National Institute For Clinical Excellence (NICE)</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>360</volume>(<issue>9334</issue>):<fpage>711</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X12451058">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
</person-group>. <source>Uncertain Judgements: Eliciting Experts’ Probabilities</source>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr3-0272989X12451058">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Philbeck</surname><given-names>TE</given-names><suffix>Jr.</suffix></name>
<name><surname>Whittington</surname><given-names>KT</given-names></name>
<name><surname>Millsap</surname><given-names>MH</given-names></name>
<name><surname>Briones</surname><given-names>RB</given-names></name>
<name><surname>Wight</surname><given-names>DG</given-names></name>
<name><surname>Schroeder</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>The clinical and cost effectiveness of externally applied negative pressure wound therapy in the treatment of wounds in home healthcare Medicare patients</article-title>. <source>Ostomy Wound Manage</source>. <year>1999</year>;<volume>45</volume>(<issue>11</issue>):<fpage>41</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X12451058">
<label>4.</label>
<citation citation-type="book">
<collab>Kinetic Concepts Inc.</collab> <source>Science Behind the Therapy: Understanding the Science of V.A.C. Therapy</source>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Kinetic Concepts Inc.</publisher-name> <year>2010</year>.</citation>
</ref>
<ref id="bibr5-0272989X12451058">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witkowski</surname><given-names>W</given-names></name>
<name><surname>Jawien</surname><given-names>A</given-names></name>
<name><surname>Witkiewicz</surname><given-names>W</given-names></name>
<name><surname>Zon</surname><given-names>B</given-names></name>
</person-group>. <article-title>Initial multi-centre observations upon the effect of a new topical negative pressure device upon patient and clinician experience and the treatment of wounds</article-title>. <source>Int Wound J</source>. <year>2009</year>;<volume>6</volume>(<issue>2</issue>):<fpage>167</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X12451058">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vella</surname><given-names>K</given-names></name>
<name><surname>Goldfrad</surname><given-names>C</given-names></name>
<name><surname>Rowan</surname><given-names>K</given-names></name>
<name><surname>Bion</surname><given-names>J</given-names></name>
<name><surname>Black</surname><given-names>N</given-names></name>
</person-group>. <article-title>Use of consensus development to establish national research priorities in critical care</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>320</volume>(<issue>7240</issue>):<fpage>976</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X12451058">
<label>7.</label>
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence</collab>. <article-title>Guide to the Methods of Technology Appraisal</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>NICE</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr8-0272989X12451058">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soares</surname><given-names>MO</given-names></name>
<name><surname>Bojke</surname><given-names>L</given-names></name>
<name><surname>Dumville</surname><given-names>JC</given-names></name>
<name><surname>Iglesias</surname><given-names>CP</given-names></name>
<name><surname>Cullum</surname><given-names>NA</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>Methods to elicit experts’ beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration</article-title>. <source>Stat Med</source>. <year>2011</year>. ;<volume>30</volume>(<issue>19</issue>):<fpage>2363</fpage>–<lpage>2380</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X12451058">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Sculpher</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Decision Modelling for Health Economic Evaluation</article-title>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr10-0272989X12451058">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies</article-title>. <source>J Health Econ</source>. <year>1999</year>;<volume>18</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X12451058">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty: when is there sufficient evidence?</article-title> <source>Value Health</source>. <year>2005</year>;<volume>8</volume>(<issue>4</issue>):<fpage>433</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X12451058">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>Expected value of sample information calculations in medical decision modelling</article-title>. <source>Med Decis Making</source>. <year>2004</year>;<volume>24</volume>(<issue>2</issue>):<fpage>207</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X12451058">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stevenson</surname><given-names>MD</given-names></name>
<name><surname>Jones</surname><given-names>ML</given-names></name>
</person-group>. <article-title>The cost-effectiveness of a randomized controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate</article-title>. <source>Med Decis Making</source>. <year>2011</year>;<volume>31</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X12451058">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Philips</surname><given-names>Z</given-names></name>
<name><surname>Ginnelly</surname><given-names>L</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Review of guidelines for good practice in decision-analytic modelling in health technology assessment</article-title>. <source>Health Technol Assess</source>. <year>2004</year>;<volume>8</volume>(<issue>36</issue>):<fpage>1</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X12451058">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CN</given-names></name>
<name><surname>Reinhard</surname><given-names>ER</given-names></name>
<name><surname>Yeh</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Interim analysis of a prospective, randomized trial of vacuum-assisted closure versus the healthpoint system in the management of pressure ulcers</article-title>. <source>Ann Plast Surg</source>. <year>2002</year>;<volume>49</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X12451058">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graumlich</surname><given-names>JF</given-names></name>
<name><surname>Blough</surname><given-names>LS</given-names></name>
<name><surname>McLaughlin</surname><given-names>RG</given-names></name><etal/>
</person-group>. <article-title>Healing pressure ulcers with collagen or hydrocolloid: a randomized, controlled trial</article-title>. <source>J Am Geriatr Soc</source>. <year>2003</year>;<volume>51</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X12451058">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Belmin</surname><given-names>J</given-names></name>
<name><surname>Meaume</surname><given-names>S</given-names></name>
<name><surname>Rabus</surname><given-names>M-T</given-names></name>
<name><surname>Bohbot</surname><given-names>S</given-names></name>
</person-group>. <article-title>Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: a multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressings alone</article-title>. <source>J Am Geriatr Soc</source>. <year>2002</year>;<volume>50</volume>(<issue>2</issue>):<fpage>269</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X12451058">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kloth</surname><given-names>LC</given-names></name>
<name><surname>Berman</surname><given-names>JE</given-names></name>
<name><surname>Nett</surname><given-names>M</given-names></name>
<name><surname>Papanek</surname><given-names>PE</given-names></name>
<name><surname>Dumit-Minkel</surname><given-names>S</given-names></name>
</person-group>. <article-title>A randomized controlled clinical trial to evaluate the effects of noncontact normothermic wound therapy on chronic full-thickness pressure ulcers</article-title>. <source>Adv Skin Wound Care</source>. <year>2002</year>;<volume>15</volume>(<issue>6</issue>):<fpage>270</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr19-0272989X12451058">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sopata</surname><given-names>M</given-names></name>
<name><surname>Luczak</surname><given-names>J</given-names></name>
<name><surname>Ciupinska</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effect of bacteriological status on pressure ulcer healing in patients with advanced cancer</article-title>. <source>J Wound Care</source>. <year>2002</year>;<volume>11</volume>(<issue>3</issue>):<fpage>107</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X12451058">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Honde</surname><given-names>C</given-names></name>
<name><surname>Derks</surname><given-names>C</given-names></name>
<name><surname>Tudor</surname><given-names>D</given-names></name>
</person-group>. <article-title>Local treatment of pressure sores in the elderly: amino acid copolymer membrane versus hydrocolloid dressing</article-title>. <source>J Am Geriatr Soc</source>. <year>1994</year>;<volume>42</volume>(<issue>11</issue>):<fpage>1180</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X12451058">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matzen</surname><given-names>S</given-names></name>
<name><surname>Peschardt</surname><given-names>A</given-names></name>
<name><surname>Alsbjørn</surname><given-names>B</given-names></name>
</person-group>. <article-title>A new amorphous hydrocolloid for the treatment of pressure sores: a randomised controlled study</article-title>. <source>Scand J Plast Reconstr Surg Hand Surg</source>. <year>1999</year>;<volume>33</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X12451058">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burgos</surname><given-names>A</given-names></name>
<name><surname>Gimenez</surname><given-names>J</given-names></name>
<name><surname>Moreno</surname><given-names>E</given-names></name><etal/>
</person-group>. <article-title>Cost, efficacy, efficiency and tolerability of collagenese ointment versus hydrocolloid occlusive dressing in the treatment of pressure ulcers</article-title>. <source>Clin Drug Invest</source>. <year>2000</year>;<volume>19</volume>:<fpage>357</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X12451058">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitney</surname><given-names>JD</given-names></name>
<name><surname>Salvadalena</surname><given-names>G</given-names></name>
<name><surname>Higa</surname><given-names>L</given-names></name>
<name><surname>Mich</surname><given-names>M</given-names></name>
</person-group>. <article-title>Treatment of pressure ulcers with noncontact normothermic wound therapy: healing and warming effects</article-title>. <source>J Wound Ostomy Continence Nurs</source>. <year>2001</year>;<volume>28</volume>(<issue>5</issue>):<fpage>244</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X12451058">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>E</given-names></name>
<name><surname>van Leen</surname><given-names>MW</given-names></name>
<name><surname>Bergemann</surname><given-names>R</given-names></name>
</person-group>. <article-title>Economic evaluation of collagenase-containing ointment and hydrocolloid dressing in the treatment of pressure ulcers</article-title>. <source>Pharmacoeconomics</source>. <year>2001</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1209</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X12451058">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Price</surname><given-names>P</given-names></name>
<name><surname>Bale</surname><given-names>S</given-names></name>
<name><surname>Crook</surname><given-names>H</given-names></name>
<name><surname>Harding</surname><given-names>K</given-names></name>
</person-group>. <article-title>The effect of a radiant heat dressing on pressure ulcers</article-title>. <source>J Wound Care</source>. <year>2000</year>;<volume>9</volume>(<issue>4</issue>):<fpage>201</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X12451058">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>DR</given-names></name>
<name><surname>Diebold</surname><given-names>MR</given-names></name>
<name><surname>Eggemeyer</surname><given-names>LM</given-names></name>
</person-group>. <article-title>A controlled, randomized, comparative study of a radiant heat bandage on the healing of stage 3-4 pressure ulcers: a pilot study</article-title>. <source>J Am Med Dir Assoc.</source> <year>2005</year>;<volume>6</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X12451058">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caldwell</surname><given-names>DM</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Higgins</surname><given-names>JPT</given-names></name>
</person-group>. <article-title>Simultaneous comparison of multiple treatments: combining direct and indirect evidence</article-title>. <source>BMJ</source>. <year>2005</year>;<volume>331</volume>(<issue>7521</issue>):<fpage>897</fpage>–<lpage>900</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X12451058">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nixon</surname><given-names>RM</given-names></name>
<name><surname>Bansback</surname><given-names>N</given-names></name>
<name><surname>Brennan</surname><given-names>A</given-names></name>
</person-group>. <article-title>Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>6</issue>):<fpage>1237</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X12451058">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Essex</surname><given-names>HN</given-names></name>
<name><surname>Clark</surname><given-names>M</given-names></name>
<name><surname>Sims</surname><given-names>J</given-names></name>
<name><surname>Warriner</surname><given-names>A</given-names></name>
<name><surname>Cullum</surname><given-names>N</given-names></name>
</person-group>. <article-title>Health-related quality of life in hospital inpatients with pressure ulceration: assessment using generic health-related quality of life measures</article-title>. <source>Wound Repair Regen</source>. <year>2009</year>;<volume>17</volume>(<issue>6</issue>):<fpage>797</fpage>–<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr30-0272989X12451058">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brazier</surname><given-names>J</given-names></name>
<name><surname>Usherwood</surname><given-names>T</given-names></name>
<name><surname>Harper</surname><given-names>R</given-names></name>
<name><surname>Thomas</surname><given-names>K</given-names></name>
</person-group>. <article-title>Deriving a preference-based single index from the UK SF-36 Health Survey</article-title>. <source>J Clin Epidemiol</source>. <year>1998</year>;<volume>51</volume>(<issue>11</issue>):<fpage>1115</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X12451058">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bennett</surname><given-names>G</given-names></name>
<name><surname>Dealey</surname><given-names>C</given-names></name>
<name><surname>Posnett</surname><given-names>J</given-names></name>
</person-group>. <article-title>The cost of pressure ulcers in the UK</article-title>. <source>Age Ageing</source>. <year>2004</year>;<volume>33</volume>:<fpage>230</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr32-0272989X12451058">
<label>32.</label>
<citation citation-type="gov">
<collab>Office for National Statistics</collab>. <article-title>Interim life tables</article-title>. <year>2007</year>. <ext-link ext-link-type="uri" xlink:href="http://www.statistics.gov.uk">http://www.statistics.gov.uk</ext-link>.</citation>
</ref>
<ref id="bibr33-0272989X12451058">
<label>33.</label>
<citation citation-type="gov">
<collab>Office for National Statistics</collab>. <article-title>Population estimates</article-title>. <month>August</month> <year>2009</year>. <ext-link ext-link-type="uri" xlink:href="http://www.statistics.gov.uk">http://www.statistics.gov.uk</ext-link>.</citation>
</ref>
<ref id="bibr34-0272989X12451058">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garthwaite</surname><given-names>PH</given-names></name>
<name><surname>Kadane</surname><given-names>JB</given-names></name>
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
</person-group>. <article-title>Statistical methods for eliciting probability distributions</article-title>. <source>J Am Stat Assoc</source>. <year>2005</year>;<volume>100</volume>:<fpage>680</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X12451058">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kadane</surname><given-names>JB</given-names></name>
<name><surname>Wolfson</surname><given-names>LJ</given-names></name>
</person-group>. <article-title>Experiences in elicitation</article-title>. <source>Statistician</source>. <year>1998</year>;<volume>47</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X12451058">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choy</surname><given-names>SL</given-names></name>
<name><surname>O’Leary</surname><given-names>R</given-names></name>
<name><surname>Mengersen</surname><given-names>K</given-names></name>
</person-group>. <article-title>Elicitation by design in ecology: using expert opinion to inform priors for Bayesian statistical models</article-title>. <source>Ecology</source>. <year>2009</year>;<volume>90</volume>(<issue>1</issue>):<fpage>265</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr37-0272989X12451058">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McKenna</surname><given-names>C</given-names></name>
<name><surname>McDaid</surname><given-names>C</given-names></name>
<name><surname>Suekarran</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Enhanced external counterpulsation for the treatment of stable angina and heart failure: a systematic review and economic analysis</article-title>. <source>Health Technol Assess</source>. <year>2009</year>;<volume>13</volume>(<issue>24</issue>):<fpage>1</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr38-0272989X12451058">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speight</surname><given-names>PM</given-names></name>
<name><surname>Palmer</surname><given-names>S</given-names></name>
<name><surname>Moles</surname><given-names>DR</given-names></name><etal/>
</person-group>. <article-title>The cost-effectiveness of screening for oral cancer in primary care</article-title>. <source>Health Technol Assess</source>. <year>2006</year>;<volume>10</volume>(<issue>14</issue>):<fpage>1</fpage>–<lpage>144</lpage>.</citation>
</ref>
<ref id="bibr39-0272989X12451058">
<label>39.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ouchi</surname><given-names>F</given-names></name>
</person-group>. <article-title>A Literature Review on the Use of Expert Opinion in Probabilistic Risk Analysis</article-title>. World Bank Policy Research Working Paper 3201. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>World Bank</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr40-0272989X12451058">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clemen</surname><given-names>RT</given-names></name>
<name><surname>Winkler</surname><given-names>RL</given-names></name>
</person-group>. <article-title>Combining probability distributions from experts in risk analysis</article-title>. <source>Risk Anal</source>. <year>1999</year>;<volume>19</volume>(<issue>2</issue>):<fpage>187</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr41-0272989X12451058">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
<name><surname>Myles</surname><given-names>JP</given-names></name>
<name><surname>Jones</surname><given-names>DR</given-names></name>
<name><surname>Abrams</surname><given-names>KR</given-names></name>
</person-group>. <article-title>Bayesian methods in health technology assessment: a review</article-title>. <source>Health Technol Assess</source>. <year>2000</year>;<volume>4</volume>(<issue>38</issue>):<fpage>1</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr42-0272989X12451058">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Welton</surname><given-names>NJ</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>Estimation of Markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration</article-title>. <source>Med Decis Making</source>. <year>2005</year>;<volume>25</volume>(<issue>6</issue>):<fpage>633</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr43-0272989X12451058">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Cohen</surname><given-names>JT</given-names></name>
<name><surname>Neumann</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>When is evidence sufficient?</article-title> <source>Health Aff</source>. <year>2005</year>;<volume>24</volume>(<issue>1</issue>):<fpage>93</fpage>–<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr44-0272989X12451058">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michaels</surname><given-names>JA</given-names></name>
<name><surname>Campbell</surname><given-names>WB</given-names></name>
<name><surname>King</surname><given-names>BM</given-names></name><etal/>
</person-group>. <article-title>A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial</article-title>. <source>Health Technol Assess</source>. <year>2009</year>;<volume>13</volume>(<issue>56</issue>):<fpage>1</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr45-0272989X12451058">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iglesias</surname><given-names>CP</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
</person-group>. <article-title>Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcers</article-title>. <source>Pharmacoeconomics</source>. <year>2006</year>;<volume>24</volume>(<issue>5</issue>):<fpage>465</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr46-0272989X12451058">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brennan</surname><given-names>A</given-names></name>
<name><surname>Kharroubi</surname><given-names>SA</given-names></name>
</person-group>. <article-title>Efficient computation of partial expected value of sample information using Bayesian approximation</article-title>. <source>J Health Econ</source>. <year>2007</year>;<volume>26</volume>(<issue>1</issue>):<fpage>122</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr47-0272989X12451058">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tappenden</surname><given-names>P</given-names></name>
<name><surname>Chilcott</surname><given-names>JB</given-names></name>
<name><surname>Eggington</surname><given-names>S</given-names></name>
<name><surname>Oakley</surname><given-names>J</given-names></name>
<name><surname>McCabe</surname><given-names>C</given-names></name>
</person-group>. <article-title>Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis</article-title>. <source>Health Technol Assess</source>. <year>2004</year>;<volume>8</volume>(<issue>27</issue>):<fpage>1</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr48-0272989X12451058">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonald</surname><given-names>AM</given-names></name>
<name><surname>Knight</surname><given-names>RC</given-names></name>
<name><surname>Campbell</surname><given-names>MK</given-names></name><etal/>
</person-group>. <article-title>What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies</article-title>. <source>Trials</source>. <year>2006</year>;<volume>7</volume>:<fpage>9</fpage>.</citation>
</ref>
<ref id="bibr49-0272989X12451058">
<label>49.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bolstad</surname><given-names>WM</given-names></name>
</person-group>. <article-title>Introduction to Bayesian Statistics</article-title>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr50-0272989X12451058">
<label>50.</label>
<citation citation-type="book">
<collab>Kinetic Concepts Inc.</collab> <article-title>V.A.C. Therapy Clinical Guidelines: A Reference Source for Clinicians</article-title>. <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Kinetic Concepts Inc.</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr51-0272989X12451058">
<label>51.</label>
<citation citation-type="book">
<collab>Department of Health</collab>. <article-title>Reference Costs: 2007-2008</article-title>. <publisher-loc>London</publisher-loc>: <publisher-name>Department of Health</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr52-0272989X12451058">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vowden</surname><given-names>KR</given-names></name>
<name><surname>Vowden</surname><given-names>P</given-names></name>
</person-group>. <article-title>The prevalence, management and outcome for acute wounds identified in a wound care survey within one English health care district</article-title>. <source>J Tissue Viability</source>. <year>2009</year>;<volume>18</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>12</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>